Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk, approved for treating type 2 diabetes (Victoza) and chronic weight management (Saxenda). Administered as a once-daily injection, it works by mimicking the incretin hormone GLP-1 to stimulate insulin secretion, suppress appetite, and slow gastric emptying.
⚠️ Research Use Only: This product is intended strictly for laboratory and in-vitro research purposes only. Not approved for human or veterinary use. Not intended for ingestion, injection, or any form of human or animal consumption. By purchasing, you confirm you are a qualified researcher and will handle this product in accordance with applicable laws and regulations.
Reviews
There are no reviews yet.